Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Basit Öğe Kaydı
dc.authoridYigenoglu, Tugce/0000-0001-9962-8882
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBirinci, Suayip/0000-0001-8104-6198
dc.authoridHacıbekiroğlu, Tuba/0000-0003-1814-5972
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridBasturk, Abdulkadir/0000-0003-1864-0316
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidCaglayan, Murat/AGY-9057-2022
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBirinci, Suayip/JFJ-4049-2023
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.contributor.authorBasci, Semih
dc.contributor.authorAta, Naim
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorNamdaroglu, Sinem
dc.date.accessioned2024-08-04T20:48:53Z
dc.date.available2024-08-04T20:48:53Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 patients without cancer at a 3/1 ratio (n = 48), diagnosed between March 11, 2020 and May 22, 2020 and included in the Republic of Turkey, Ministry of Health database, were analyzed retrospectively. Results The rates of intensive care unit (ICU) admission, and mechanical ventilation (MV) support were lower in CML patients compared to the control group, however, these differences did not achieve statistical significance (p = 0.1, and p = 0.2, respectively). The length of hospital stay was shorter in CML patients compared with the control group; however, it was not statistically significant (p = 0.8). The case fatality rate (CFR) in COVID-19 patients with CML was 6.3%, and it was 12.8% in the control group. Although the CFR in CML patients with COVID-19 was lower compared to the control group, this difference did not achieve statistical significance (p = 0.5). When CML patients were divided into 3 groups according to the TKI, no significant difference was observed regarding the rate of ICU admission, MV support, CFR, the length of stay in both hospital and ICU (all p > 0.05). Conclusion This study highlights that large scale prospective and randomized studies should be conducted in order to investigate the role of TKIs in the treatment of COVID-19.en_US
dc.identifier.doi10.1177/1078155220953198
dc.identifier.endpage1682en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid32854573en_US
dc.identifier.scopus2-s2.0-85089986029en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1676en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220953198
dc.identifier.urihttps://hdl.handle.net/11616/99504
dc.identifier.volume26en_US
dc.identifier.wosWOS:000563664500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectchronic myeloid leukemiaen_US
dc.titleOutcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu